236 related articles for article (PubMed ID: 12705638)
21. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
Szot W; Kostkiewicz M; Zając J; Owoc A; Bojar I
Ann Agric Environ Med; 2014; 21(4):888-92. PubMed ID: 25528940
[TBL] [Abstract][Full Text] [Related]
23. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
[TBL] [Abstract][Full Text] [Related]
24. Detection of metastatic bone lesions in patients with prostate carcinoma: 99Tcm-monoclonal antibody imaging.
Kiraç S; Duman Y; Cüreklibatur I; Yüksel D; Nazli O; Günaydin G; Taner M
Nucl Med Commun; 1997 Oct; 18(10):968-73. PubMed ID: 9392800
[TBL] [Abstract][Full Text] [Related]
25. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
26. [Skeletal scintigraphy for the observation of course and treatment of carcinoma of the prostate ].
Pabst HW; Langhammer H; Schmid L; Sintermann R
Rofo; 1981 Jul; 135(1):44-9. PubMed ID: 6288532
[TBL] [Abstract][Full Text] [Related]
27. Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer.
Chavdarova L; Piperkova E; Tsonevska A; Timcheva K; Dimitrova M
J BUON; 2006; 11(4):499-504. PubMed ID: 17309184
[TBL] [Abstract][Full Text] [Related]
28.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
29. Prediction of tumor absorbed dose by Tc-99m-MDP scintigraphy prior to treatment with Sr-89.
Manetou A; Limourls GS
Anticancer Res; 1997; 17(3B):1845-7. PubMed ID: 9179243
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases].
Senkus-Konefka E; Krasińska L; Pikiel J; Krasińska W; Nowaczyk M; Jassem J
Przegl Lek; 2003; 60(7):467-70. PubMed ID: 14750420
[TBL] [Abstract][Full Text] [Related]
31. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
Lin Y; Mao Q; Chen B; Wang L; Liu B; Zheng X; Xie L
BMC Urol; 2017 Jun; 17(1):41. PubMed ID: 28606069
[TBL] [Abstract][Full Text] [Related]
32. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
34. Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. on bone scintigraphy in patients with newly diagnosed prostate carcinoma.
Jacobson AF
Nucl Med Commun; 2000 Jul; 21(7):617-22. PubMed ID: 10994663
[TBL] [Abstract][Full Text] [Related]
35. [Patterns of bone metastases of carcinoma of the prostate: evaluation using 99mTC-MDP bone scintigraphy].
Matsuda H; Sakashita S; Arakawa M; Koyanagi T
Nihon Hinyokika Gakkai Zasshi; 1987 Oct; 78(10):1809-13. PubMed ID: 3444173
[No Abstract] [Full Text] [Related]
36. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
[TBL] [Abstract][Full Text] [Related]
37. [Scintigraphic control of bone metastases of prostatic cancer treated with cytonal and cyclophosphamide].
Grossmann J; Weiss M; Deckart H; Raatzsch H
Radiobiol Radiother (Berl); 1988; 29(6):736-8. PubMed ID: 3253797
[No Abstract] [Full Text] [Related]
38. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?
Yap BK; Choo R; Deboer G; Klotz L; Danjoux C; Morton G
BJU Int; 2003 May; 91(7):613-7. PubMed ID: 12699470
[TBL] [Abstract][Full Text] [Related]
39. Relation between pain and skeletal metastasis in patients with prostate or breast cancer.
Levren G; Sadik M; Gjertsson P; Lomsky M; Michanek A; Edenbrandt L
Clin Physiol Funct Imaging; 2011 May; 31(3):193-5. PubMed ID: 21114613
[TBL] [Abstract][Full Text] [Related]
40. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
